<DOC>
	<DOCNO>NCT00457938</DOCNO>
	<brief_summary>Lipodystrophies represent therapeutic challenge regard management diabetes , insulin resistance , hypertriglyceridemia fatty liver frequently present conjunction significant adipose tissue loss . The purpose study 's four subprojects examine safety efficacy various novel intervention design improve resolve fatty liver , hypertriglyceridemia , insulin resistance diabetes see patient .</brief_summary>
	<brief_title>Novel Therapies Metabolic Complications Lipodystrophies</brief_title>
	<detailed_description>We propose novel therapeutic approach management metabolic complication patient lipodystrophies . The four intervention test : Hypothesis 1 : An extremely low fat diet . Hypothesis 2 : Leptin replacement therapy . Hypothesis 3 : Cholic acid therapy.. Hypothesis 4 : Peroxisome proliferator activate receptor ( PPAR ) agonist , pioglitazone .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<criteria>General Inclusion criterion : Patients lipodystrophies diagnose clinical criterion Any one following : Diabetes mellitus , Fasting serum triglyceride great 200 mg/dL , Fasting serum insulin great 30 U/mL , Hepatic steatosis ( great 5.6 % hepatic triglyceride content ) demonstrate 1H MRS . Known liver disease due cause nonalcoholic steatohepatitis : Current alcohol abuse ( 7 drink 210 g per wk woman 14 drink 420 g per wk men ) . Positive serological marker hepatitis B C. Autoimmune hepatitis , autoimmune cholestatic liver disorder , Wilson disease Alpha1antitrypsin deficiency indicate clinical laboratory test . Druginduced liver disease Evidence hepatocellular carcinoma : alphafetoprotein level great 200 ng/ml and/or liver mass image study suggestive liver cancer . Decompensated liver disease evidence clinical feature hepatic failure ( variceal bleeding , ascites , hepatic encephalopathy etc . ) laboratory investigation ( prolonged prothrombin time , hypoalbuminemia , presence esophageal varix etc . ) Use drug potentially decrease hepatic steatosis previous 3 month ; highdose vitamin E , betaine , acetylcysteine , choline probucol . Significant systemic major illness liver disease ( congestive heart failure , unstable angina , cerebrovascular disease , respiratory failure , renal failure [ serum creatinine 2 mg/dL ] , acute pancreatitis , organ transplantation , serious psychiatric disease , malignancy ) could interfere trial adequate follow . Acute medical illness preclude participation study . Known HIV infected patient . Current substance abuse . Pregnant lactating woman . Hematocrit le 30 % . History weight loss ( 10 % ) use weight loss drug sibutramine orlistat last 3 month . Each subproject additional specific inclusion exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>lipodystrophy</keyword>
</DOC>